Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): Subset analysis of the DASISION trial with 2-year follow-up.

Shin Fujisawa, Hirohisa Nakamae, Michinori Ogura, Ken ichi Ishizawa, Masafumi Taniwaki, Atae Utsunomiya, Kosei Matsue, Yasushi Takamatsu, Kensuke Usuki, Mitsune Tanimoto, Yoji Ishida, Hideki Akiyama, Shintaro Onishi

    Research output: Contribution to journalArticlepeer-review

    27 Citations (Scopus)

    Fingerprint

    Dive into the research topics of 'Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): Subset analysis of the DASISION trial with 2-year follow-up.'. Together they form a unique fingerprint.

    Medicine & Life Sciences